All In Biotech

Drug Trial Radar · NCT05171647

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 208 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

208

Actual

Start

Apr 25, 2022

Primary completion

Feb 17, 2025

Study completion Feb 28, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).

Conditions

  • Non-Hodgkin Lymphoma

Interventions

  • MosunetuzumabDrug

    Participants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).

  • Polatuzumab vedotinDrug

    Participants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).

  • TocilizumabDrug

    Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.

  • RituximabDrug

    Participants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).

  • GemcitabineDrug

    Participants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).

  • OxaliplatinDrug

    Participants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)Time frame: Up to approximately 23.8 months
  2. Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT ScansTime frame: Up to 32 months

Locations

50 sites in 13 countries. Site status is shown where the registry gives one.

  • City of Hope Cancer Center

    Duarte, California

  • St. Luke's Hospital

    Chesterfield, Missouri

  • Ascension Seton Infusion Center

    Austin, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Hospital Aleman

    Buenos Aires, Argentina

  • Instituto Alexander Fleming

    Buenos Aires, Argentina

  • FUNDALEU

    Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires

    Ciudad Autonoma Buenos Aires, Argentina

  • D'or Instituto de Pesquisa e Educação

    São Paulo, Brazil

  • Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital das Clínicas FMRP-USP

    Ribeirão Preto, São Paulo, Brazil

  • Hospital Sao Jose

    São Paulo, São Paulo, Brazil

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Chum Hopital Notre Dame

    Montreal, Quebec, Canada

  • Sichuan Cancer Hospital

    Chengdu, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Cancer Center, Sun Yat-sen University of Medical Sciences

    Guangzhou, China

  • Tianjin Cancer Hospital

    Tianjin, China

  • Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech

    Wuhan, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Soroka Medical Center

    Beersheba, Israel

  • Ichilov Sourasky Medical Center

    Tel Aviv, Israel

  • Kyushu University Hospital

    Fukuoka, Japan

  • Hokkaido University Hospital

    Hokkaido, Japan

  • Tohoku University Hospital

    Miyagi, Japan

  • Kindai University Hospital

    Osaka, Japan

  • The Cancer Institute Hospital of JFCR

    Tokyo, Japan

  • Yamagata University Hospital

    Yamagata, Japan

  • Instituto Nacional de Cancerologia

    Distrito Federal, Mexico

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    México, Mexico

  • Superare Centro de Infusion S.A. de C.V.

    Mexico City, Mexico CITY (federal District), Mexico

  • Hospital Universitario Dr. Jose E. Gonzalez

    Monterrey, Nuevo León, Mexico

  • Middlemore Clinical Trials

    Auckland, New Zealand

  • Instituto Regional de Enfermedades Neoplásicas del Sur

    Arequipa, Peru

  • Oncosalud Sac

    Lima, Peru

  • Pusan National University Hospital

    Busan, South Korea

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.